Description
AICAR Vials
AICAR | |
CAS Number | 2627-69-2 |
Molar Mass | 258.23g.mol-1 |
Chemical Formula | C9H14N4O5 |
IUPAC Name | N1-(β-D-Ribofuranosyl)-5-aminoimidazole-4-carboxamide |
Introduction
AICAR Vials are a research product developed for scientific investigations and experimentation, strictly intended for research purposes only. AICAR, or 5-Aminoimidazole-4-carboxamide ribonucleotide, is a synthetic compound known for its potential applications in various research fields.
Key Characteristics
AICAR Vials contain high-purity AICAR, ensuring consistency and reliability in research settings. The vials are designed to provide researchers with a controlled and measurable dosage for their experiments.
Research Applications
AICAR Vials have diverse applications in scientific research, with a focus on understanding the compound’s impact on metabolic pathways, cellular functions, and physiological responses.
Research Benefits
AICAR and Diabetes
Numerous studies have explored the potential of AICAR in addressing diabetes-related issues. Research suggests that AICAR may play a role in regulating glucose metabolism and insulin sensitivity. The compound has shown promise in preclinical models for mitigating aspects of diabetes-associated complications.
AICAR and Brain Functions
AICAR’s impact on brain functions has been a subject of interest in neuroscience research. Preliminary studies indicate that AICAR may have neuroprotective properties and could influence factors related to cognitive functions and neurological disorders.
AICAR and Heart Health
In cardiovascular research, AICAR has been investigated for its potential benefits on heart health. Research suggests that AICAR may have cardioprotective effects, influencing factors such as myocardial ischemia and cardiac function.
Summary
AICAR Vials offer a valuable tool for researchers aiming to explore the diverse applications of AICAR in various scientific domains. From diabetes-related studies to investigations into brain functions and heart health, the controlled dosage provided by AICAR Vials facilitates precise experimentation.
References
- Winder WW. Can patients with type 2 diabetes be treated with 5′-AMP-activated protein kinase activators? Diabetologia. 2008 Oct;51(10):1761-4. doi: 10.1007/s00125-008-1115-8. Epub 2008 Aug 12. PMID: 18696044; PMCID: PMC2730159. [Read More]
- Kobilo T, Guerrieri D, Zhang Y, Collica SC, Becker KG, van Praag H. AMPK agonist AICAR improves cognition and motor coordination in young and aged mice. Learn Mem. 2014 Jan 17;21(2):119-26. doi: 10.1101/lm.033332.113. PMID: 24443745; PMCID: PMC3895225. [Read More]
- Banek CT, Bauer AJ, Needham KM, Dreyer HC, Gilbert JS. AICAR administration ameliorates hypertension and angiogenic imbalance in a model of preeclampsia in the rat. Am J Physiol Heart Circ Physiol. 2013 Apr 15;304(8):H1159-65. doi: 10.1152/ajpheart.00903.2012. Epub 2013 Feb 15. PMID: 23417865; PMCID: PMC3625906. [Read More]
Reviews
There are no reviews yet.